PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Falkenberg, N. ; Anastasov, N. ; Rappl, K. ; Braselmann, H. ; Auer, G.* ; Walch, A.K. ; Huber, M. ; Höfig, I. ; Schmitt, M.* ; Höfler, H. ; Atkinson, M.J. ; Aubele, M.

MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion.

Br. J. Cancer 109, 2714-2723 (2013)
Verlagsversion Volltext DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Background:MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells.Methods:MiR-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT-PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222.Results:In tumour tissues, miR-221/-222 were associated with the occurrence of distant metastases. In particular, high levels of miR-221 were revealed to have a high prognostic impact for the identification of significantly different groups with advanced tumours. MiR-221/-222 overexpression strongly increased cell proliferation and invasion in vitro. Following miR-221/-222 overexpression an increased uPAR expression and cell invasion were observed.Conclusion:This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
5.082
1.730
45
48
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Therapy ; Prognosticator ; Prognosis ; Metastasis ; Malignancy ; Mir-221 ; Mir-222 ; Urokinase-type Plasminogen Activator System ; Upar; Urokinase Plasminogen-activator ; Estrogen-receptor-alpha ; Messenger-rna ; Tamoxifen Resistance ; Down-regulation ; Expression ; Micrornas ; Metastasis ; Survival ; Mir-222
Sprache englisch
Veröffentlichungsjahr 2013
HGF-Berichtsjahr 2013
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Zeitschrift British Journal of Cancer BJC
Quellenangaben Band: 109, Heft: 10, Seiten: 2714-2723 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pathology (PATH)
Institute of Radiation Biology (ISB)
Translational Metabolic Oncology (IDC-TMO)
Research Unit Analytical Pathology (AAP)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30202 - Environmental Health
30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
Radiation Sciences
PSP-Element(e) G-500300-001
G-500200-001
G-501000-001
G-500390-001
PubMed ID 24129242
DOI 10.1038/bjc.2013.625
WOS ID WOS:000327128200024
Scopus ID 84887840885
Erfassungsdatum 2013-10-25
[➜Korrektur melden]